Riboflavin 5'-Phosphate · ophthalmic kit
Misc.
Approved uses
Progressive keratoconus and corneal ectasia following refractive surgery
Epithelium debrided to about 9 mm, then 1 drop of Photrexa Viscous every 2 minutes for 30 minutes; once yellow flare is seen and corneal thickness is at least 400 microns, irradiate for 30 minutes at 3mW/cm2 with the KXL System while continuing Photrexa Viscous every 2 minutes
The epithelium-off protocol: it hurts and it heals slowly, which is the trade for the strongest evidence base
Contraindications
None.
Kit of one PHOTREXA VISCOUS 0.146% (1.56 mg/mL, in 20% dextran) and one PHOTREXA 0.146% (1.46 mg/mL), each in a 3 mL glass syringe
Riboflavin 5'-phosphate sodium (Vitamin B2) is the precursor of two coenzymes, flavin adenine dinucleotide and flavin mononucleotide, which catalyze oxidation/reduction reactions involved in a number of metabolic pathways. Under the conditions used for corneal collagen cross-linking, riboflavin 5'-phosphate functions as a photoenhancer and generates singlet oxygen which is responsible for the cross-linking.
Warnings & Precautions
Ulcerative keratitis: Ulcerative keratitis can occur. Monitor for resolution of epithelial defects.
Common Side Effects
In progressive keratoconus patients, the most common ocular adverse reactions in any CXL-treated eye were corneal opacity (haze), punctate keratitis, corneal striae, corneal epithelium defect, eye pain, reduced visual acuity, and blurred vision. In corneal ectasia patients, the most common ocular adverse reactions were corneal opacity (haze), corneal epithelium defect, corneal striae, dry eye, eye pain, punctate keratitis, photophobia, reduced visual acuity, and blurred vision.
Pregnancy: Animal development and reproduction studies have not been conducted. Since it is not known whether the corneal collagen cross-linking procedure can cause fetal harm or affect reproduction capacity, it should not be performed on pregnant women.
Lactation: There are no data on the presence of PHOTREXA VISCOUS or PHOTREXA in human milk, the effects on the breastfed infant, or the effects on milk production.
The safety and effectiveness of corneal collagen cross-linking has not been established in pediatric patients below the age of 14 years.